What is Ora?
Ora operates as a premier full-service ophthalmic clinical research and product development firm. With a legacy spanning over 45 years, the company has established an unparalleled track record, having successfully managed more than 3,000 clinical projects. Their expertise is instrumental in the regulatory pathway, having facilitated the market approval of over 85 drugs and devices. By bridging the gap between early-stage innovation and commercial viability, Ora serves as a critical partner for biotech and pharmaceutical entities navigating the complex regulatory environment of ophthalmology.
The firm's market position is defined by its deep domain expertise and its ability to execute large-scale, multi-center trials. Unlike generalist contract research organizations, Ora provides a specialized infrastructure that accelerates the development of novel therapies for ocular diseases, ensuring that high-quality data is generated to meet the rigorous standards of global health authorities.
How much funding has Ora raised?
Ora has raised a total of $2M across 1 funding round:
Debt
$2M
Debt (2020): $2M with participation from PPP
Key Investors in Ora
PPP
Public-Private Partnership
What's next for Ora?
With this major enterprise-level funding, Ora is well-positioned to scale its operational capabilities and expand its footprint in the global ophthalmic market. The strategic allocation of these resources will likely focus on enhancing their proprietary clinical trial methodologies and investing in advanced diagnostic technologies. As the pipeline for ophthalmic therapeutics continues to diversify, Ora's role as a strategic partner will be pivotal in navigating the next generation of drug and device approvals. The firm is expected to leverage this financial momentum to further solidify its leadership, potentially exploring new therapeutic areas within the eye care spectrum and strengthening its international research network to meet the evolving needs of its global client base.
See full Ora company page
